Sodium Acetate
CAS 127-09-3
Sodium Acetate (CAS 127-09-3) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 14 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 18033.333333333332 nM | 3 | - |
| Carbonic anhydrase 1 Enzyme |
Ki | 4.97 | - | Homo sapiens |
| Carbonic anhydrase Enzyme |
Ki | 4.44 | - | Candida albicans (strain SC5314 / ATCC MYA-2876) |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Toxic anterior segment syndrome | 177 | 1296.344 | 10066366 |
| Endophthalmitis | 73 | 397.936 | 10014801 |
| Post procedural complication | 46 | 174.247 | 10058046 |
| Anterior chamber cell | 27 | 173.023 | 10053781 |
| Cataract operation complication | 19 | 137.273 | 10057419 |
| Eye inflammation | 28 | 123.783 | 10015943 |
| Anterior chamber disorder | 12 | 84.461 | 10061641 |
| Corneal oedema | 16 | 78.869 | 10011033 |
| Keratitis | 17 | 75.651 | 10023332 |
| Anterior chamber inflammation | 11 | 64.844 | 10054765 |
| Iridocyclitis | 13 | 56.187 | 10022941 |
| Intraocular pressure increased | 15 | 52.564 | 10022806 |
| Foetal growth restriction | 15 | 49.26 | 10070531 |
| Corneal opacity | 9 | 45.574 | 10011035 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Sodium Acetate | 56443 | SU | MTHSPL |
| SODIUM ACETATE | 56443 | SU | MTHSPL |
| Sodium acetate | 56443 | SU | MTHSPL |
| sodium acetate | 56443 | SU | MTHSPL |
| Sodium Acetate Anhydrous | 267453 | SU | MTHSPL |
| SODIUM ACETATE ANHYDROUS | 267453 | SU | MTHSPL |
| sodium acetate anhydrous | 267453 | SU | MTHSPL |
| sodium acetate | 56443 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Acetate used for in pharmaceutical contexts?
Sodium Acetate (CAS 127-09-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Acetate?
Sodium Acetate has 14 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Toxic anterior segment syndrome, Endophthalmitis, Post procedural complication, Anterior chamber cell, Cataract operation complication. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Acetate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Acetate with EU status "restricted".
What clinical phase is Sodium Acetate in?
Sodium Acetate is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Sodium Acetate?
Sodium Acetate has 3 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 1, Carbonic anhydrase.